Company Description

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.

Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.

The company was founded in 2019 and is based in Naples, Florida.

Conduit Pharmaceuticals Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Andrew Regan

Contact Details

Address: 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 United States
Phone	(646)-491-9132
Website	conduitpharma.com

Stock Details

Ticker Symbol	CDT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001896212
CUSIP Number	20678X106
ISIN Number	US20678X1063
Employer ID	87-3272543
SIC Code	2834

Key Executives

Name	Position
Dr. Andrew Regan	Founder, Chief Executive Officer and Director
James Bligh	Interim Chief Financial Officer and Director
Dr. David Joszef Tapolczay	Head of Strategy and Licensing
Dr. Joanne M. Holland	Chief Scientific Officer

Latest SEC Filings

Date	Type	Title
Jul 31, 2025	SCHEDULE 13D/A	Filing
Jul 31, 2025	S-3	Registration statement under Securities Act of 1933
Jul 8, 2025	DEF 14A	Other definitive proxy statements
Jul 8, 2025	ARS	Filing
Jun 9, 2025	8-K	Current Report
Jun 3, 2025	8-K	Current Report
May 16, 2025	8-K	Current Report
May 15, 2025	SCHEDULE 13G	Filing
May 15, 2025	10-Q	Quarterly Report
May 7, 2025	SCHEDULE 13G	Filing

View All SEC Filings